Literature DB >> 35765518

A CB2 Receptor Agonist Reduces the Production of Inflammatory Mediators and Improves Locomotor Activity in Experimental Autoimmune Encephalomyelitis.

Karim Parastouei1, Mohammad Hossein Aarabi2, Gholam Ali Hamidi3, Zahra Nasehi3, Shima Kabiri-Arani3, Faezeh Jozi3, Mohammad Esmaeil Shahaboddin4.   

Abstract

Background: Cannabinoids (CBs) have been found to regulate the immune system, affect innate and adaptive immune responses, and reduce inflammatory reactions. This study assessed the therapeutic effects of GW-405833 synthetic CB2 agonist on inflammatory factors as well as locomotor activity in experimental autoimmune encephalomyelitis (EAE).
Methods: In this experimental study, 48 adult male C57BL/6 mice were randomly and equally assigned to eight groups. By injecting 250 mg of MOG35-55 peptide, EAE was induced. Every other day for 17 days after EAE onset, EAE-afflicted mice in groups 1-3 received an intraperitoneal injection of GW-405833 at a dose of 3, 10, and 30 mg/kg, respectively. Clinical status and locomotor activity, measured using the beam walking assay, were assessed every other day during the first 17 days after EAE onset. Mice were euthanized in day 17th of treatment and the serum levels of the IL-1β, IL-12, CRP, and TNF-α proinflammatory cytokines as well as IL-4 and TGF-β anti-inflammatory cytokines were measured by ELISA method.
Results: Clinical manifestations of EAE in groups 2 and 3 were significantly milder than group 4 and locomotor activity in groups 1-3 was significantly better than group 4 in days 5-17 (p< 0.05). GW-405833 also significantly decreased the levels of IL-12, TNF-α, and CRP and significantly increased the levels of IL-4 and TGF-β but had no significant effects on the level of IL-1β. GW-405833 was not associated with significant side effects.
Conclusion: The CB2 receptor agonist GW-405833, improves clinical conditions and reduces inflammation in mice with EAE.

Entities:  

Keywords:  Clinical evaluation; Experimental autoimmune encephalomyelitis; GW-405833; Locomotor activity; Multiple sclerosis; Proinflammatory cytokines

Year:  2022        PMID: 35765518      PMCID: PMC9208571          DOI: 10.52547/rbmb.11.1.1

Source DB:  PubMed          Journal:  Rep Biochem Mol Biol        ISSN: 2322-3480


  35 in total

1.  Efficient testing of motor function in spinal cord injured rats.

Authors:  G A Metz; D Merkler; V Dietz; M E Schwab; K Fouad
Journal:  Brain Res       Date:  2000-11-17       Impact factor: 3.252

2.  Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro.

Authors:  J Visser; A van Boxel-Dezaire; D Methorst; T Brunt; E R de Kloet; L Nagelkerken
Journal:  Blood       Date:  1998-06-01       Impact factor: 22.113

3.  Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody.

Authors:  Bert A 't Hart; Herbert P M Brok; Ed Remarque; Jacqueline Benson; George Treacy; Sandra Amor; Rogier Q Hintzen; Jon D Laman; Jan Bauer; Erwin L A Blezer
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

4.  CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain.

Authors:  N Clayton; F H Marshall; C Bountra; C T O'Shaughnessy
Journal:  Pain       Date:  2002-04       Impact factor: 6.961

Review 5.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.

Authors:  J Guindon; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

6.  Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS.

Authors:  Mohab M Ibrahim; Hongfeng Deng; Alexander Zvonok; Debra A Cockayne; Joyce Kwan; Heriberto P Mata; Todd W Vanderah; Josephine Lai; Frank Porreca; Alexandros Makriyannis; T Philip Malan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-13       Impact factor: 11.205

Review 7.  Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis.

Authors:  Bert A 't Hart; Rogier Q Hintzen; Jon D Laman
Journal:  Neurodegener Dis       Date:  2008       Impact factor: 2.977

8.  The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.

Authors:  John C Ashton; Michelle Glass
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

9.  Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models.

Authors:  Ji Zhang; Cyrla Hoffert; Huy Khang Vu; Thierry Groblewski; Sultan Ahmad; Dajan O'Donnell
Journal:  Eur J Neurosci       Date:  2003-06       Impact factor: 3.386

10.  Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells.

Authors:  David M Elliott; Narendra Singh; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Front Immunol       Date:  2018-08-03       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.